Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statistical issues in studies of toxicity modifiers.

Charles Scott1

  • 1American College of Radiology, Philadelphia, PA 19107, USA.

Seminars in Radiation Oncology
|March 28, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structured Violence Risk Assessments: Generations Ahead of Clinical Judgment.

Focus (American Psychiatric Publishing)·2026
Same author

General-Purpose and Reasoning Large Language Models for Automated Abdominal CT Protocoling.

AJR. American journal of roentgenology·2025
Same author

Effects of a novel GABA-B positive allosteric modulator, ASP8062, on alcohol cue-elicited craving and naturalistic alcohol consumption in a multisite randomized, double-blind, placebo-controlled trial.

Alcohol, clinical & experimental research·2024
Same author

Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients.

Future oncology (London, England)·2023
Same author

Re/turning to soil: becoming one-bodied with the Earth.

Cultural studies of science education·2021
Same author

Recovery in glioblastoma multiforme during inpatient rehabilitation is equivalent in first versus repeat resection: A 10-year retrospective analysis.

PM & R : the journal of injury, function, and rehabilitation·2021
Same journal

Integrative Medicine for Breast Cancer Survivors.

Seminars in radiation oncology·2026
Same journal

Integrative Oncology Approaches for Gastrointestinal Symptoms and Risk Reduction in Patients With Digestive Tract Cancers.

Seminars in radiation oncology·2026
Same journal

Integrative Oncology and Radiation Therapy: An Essential Evolution.

Seminars in radiation oncology·2026
Same journal

Clinical Trials of Integrative Oncology Interventions for Radiation Therapy: Emerging Evidence and Opportunities.

Seminars in radiation oncology·2026
Same journal

Nonpharmacologic Approaches for Pain Management in Patients With Cancer Treated With Radiation Therapy.

Seminars in radiation oncology·2026
Same journal

Integrative Therapies for Radiation-Related Toxicities in Hematological Malignancies.

Seminars in radiation oncology·2026
See all related articles

Developing new cancer drugs to reduce toxicity requires different clinical trial designs. Phase I trials should focus on the maximum effective dose, not the maximum tolerated dose, for these agents.

Area of Science:

  • Oncology
  • Clinical Pharmacology
  • Drug Development

Background:

  • Cancer treatment intensity increases normal tissue toxicity.
  • Pharmacologic agents are developed to reduce treatment-related toxicities.
  • Standard drug development paradigms may not apply to toxicity-reducing agents.

Purpose of the Study:

  • To propose modified clinical trial designs for pharmacologic agents aimed at reducing cancer treatment toxicity.
  • To address the challenges in evaluating toxicity modifiers compared to traditional drug development.

Main Methods:

  • Re-evaluation of Phase I study objectives: focus on maximum effective dose (MED) instead of maximum tolerated dose (MTD).
  • Discussion of Phase II study design modifications, including the necessity of placebo-controlled, randomized trials for toxicity modifiers.

Related Experiment Videos

  • Consideration of Phase III study objectives: primary focus on toxicity amelioration/prevention, quality of life, and impact on therapeutic outcomes.

    • Main Results:

    • Standard Phase I and II trial designs are often inadequate for evaluating toxicity modifiers.
    • Placebo-controlled, randomized Phase II studies are recommended to mitigate bias in toxicity assessment.
    • Phase III trials must comprehensively assess subjective/objective toxicity, quality of life, and treatment efficacy.

    Conclusions:

    • Modified clinical trial designs are essential for the effective development of cancer treatment toxicity modifiers.
    • Accurate assessment of toxicity modifiers requires careful consideration of study design, including randomization and blinding.
    • Future research should focus on optimizing trial methodologies to ensure the safe and effective use of supportive care agents in oncology.